FDA clears Orca Bio cell therapy for blood cancer treatment
The approval of Tregzi provides a specialized alternative to traditional stem cell transplants, targeting the reduction of graft-versus-host disease.
Dr. Ines Havel
Jul 1, 2026 · 1 min read
Traditional matched-donor stem cell transplants have long presented a calculated risk for leukemia patients: the possibility of a cure balanced against the high probability of chronic graft-versus-host disease. The Food and Drug Administration has approved a new personalized T-cell therapy, developed by Orca Bio, designed to mitigate this systemic immune reaction.
The therapy, marketed as Tregzi, functions by restructuring the cellular components of a transplant to improve the patient’s underlying immune recovery without triggering the debilitating inflammation common in standard procedures. This clearance represents a move toward high-precision immunology in clinical settings, where the composition of donor material is engineered rather than merely matched by type.
Orca Bio, a private biotechnology firm, stated that the goal of the new treatment protocol is to improve survival rates that are free from the long-term complications typical of bone marrow donation. The approval establishes a new competitive standard for the standard of care in hematological oncology.